Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
72 <strong>Annual</strong> Financial Statement Konzern-Jahresabschluss<br />
Notes to the consolidated financial statements for the fiscal<br />
year from 1 July <strong>2009</strong> to 30 June <strong>2010</strong><br />
1. General Information<br />
<strong>biolitec</strong> <strong>AG</strong> and its subsidiaries produce and sell medical laser devices, drugs and disposables and are<br />
specialized in the field of medical research and development.<br />
<strong>biolitec</strong> <strong>AG</strong>, Jena, was founded on March 17, 1999 (deed roll no. 0257/1999 of German notary Herbert<br />
Freiherr von Schlotheim-Reinbrecht, Jena) with a capital stock of EUR 50,000. It is a stock corporation<br />
(Aktiengesellschaft) according to German Law. The parent company’s registered seat is: Otto-Schott-<br />
Straße 15, 07745 Jena (Germany).<br />
After the increase in capital against non-cash contributions in the scope of the contribution and post<br />
formation agreement dated 12 September 2000, on the subject of the interests held by BioMed Technology<br />
Holdings Ltd., Labuan / Malaysia (“BioMed“) in corporations, <strong>biolitec</strong> was for the first time obligated<br />
to prepare consolidated financial statements. The first set of consolidated financial statements<br />
was prepared as of June 30, 2001. June 30, is also the balance sheet date of all consolidated subsidiaries<br />
and second-tier subsidiaries, except for AndaOptec Ltd., Livani/ Latvia and <strong>biolitec</strong> Private India Ltd.,<br />
Bangalore/India (March 31). AndaOptec Ltd. prepares an interim financial statement with due date June<br />
30, and <strong>biolitec</strong> Private India Ltd., is included in the group’s financial statements in accordance with IAS<br />
27.27.<br />
On 13 November 2000, the shares of <strong>biolitec</strong> <strong>AG</strong> were admitted to the ‘Geregelter Markt’ and to trading<br />
on the ‘Neuer Markt’ of the Frankfurt/Main Stock Exchange. In the course of the new segmentation of<br />
the German stock market, <strong>biolitec</strong> <strong>AG</strong> received the approval for Prime Standard on 15 January 2003.<br />
The consolidated financial statement is presented in Euro.<br />
2. Activities of the <strong>biolitec</strong> group<br />
Biolitec is the technology leader in diode lasers, fiber-optical consumables and photo-dynamic active<br />
substances. It is the sole supplier for photodynamic therapy owning all relevant core competences<br />
(photosensitizer, laser, optical fibers and the approved cancer drug Foscan). This combination of medical<br />
technology and agent development for different medical indications distinguishes <strong>biolitec</strong>.<br />
The company operates in two domestic as well as numerous foreign locations. 75% of turnover is generated<br />
in Europe and the USA by producing and selling medical lasers, laser probes and optical fibers.